Based on trial findings, U.S. Food and Drug Administration (FDA) approval of the Insightec device was extended in November to treat moderate-to-severe motor complications, such as tremors, stiffness and dyskinesia (involuntary movement), in advanced disease patients who fail to respond to standard Parkinson’s therapies.

 

Read more here.